Category:VorinostatVorinostatVorinostatVorinostat%D9%88%D8%B1%DB%8C%D9%86%D9%88%D8%B3%D8%AA%D8%A7%D8%AAVorinostat%E3%83%9C%E3%83%AA%E3%83%8E%E3%82%B9%E3%82%BF%E3%83%83%E3%83%88WorinostatVorinostatVorinostat%D0%92%D0%BE%D1%80%D0%B8%D0%BD%D0%BE%D1%81%D1%82%D0%B0%D1%82VorinostatVorinostatVorinostatQ905901
about
sameAs
P3354
P3781
Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma MultiformePhase I Study of Vorinostat and Sorafenib in Advanced CancerPhase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)Vorinostat and Palliative RadiotherapyA Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast CancerPhase II Trial of SAHA & Tamoxifen for Patients With Breast CancerVorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the UrotheliumVorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord TumorsSorafenib and Vorinostat in Treating Patients With Advanced Liver CancerPh I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell CarcinomaVorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing RegimensVorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance TherapyA Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous SystemA Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential ThrombocythaemiaOlaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast CancerPhase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)Suberoylanilide Hydroxamic Acid in Advanced Solid TumorsVorinostat (SAHA) in Uterine SarcomaVorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple MyelomaA Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract CancerVorinostat Plus FND in Relapsed or Refractory Mantle Cell LymphomaAlisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaAzacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaStudy of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple MyelomaVorinostat in ChildrenVorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid MalignanciesSafety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral TherapyStudy of Pazopanib and Vorinostat in Patients With Advanced MalignanciesThe Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ARTMagnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive GlioblastomaA Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural MesotheliomaA Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
P4844
Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanismsSynergistic Anticancer Effects of Vorinostat and Epigallocatechin-3-Gallate against HuCC-T1 Human Cholangiocarcinoma Cells.A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.The histone deacetylase inhibitor vorinostat prevents TNFα-induced necroptosis by regulating multiple signaling pathways.Comprehensive gene expression profiles of NK cell neoplasms identify vorinostat as an effective drug candidate.A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.
P921
Q21140676-404E492B-8137-43F5-B28C-F537EF07DA04Q21154358-E215453A-62B2-4CF8-868E-65DBE980BD42Q21157551-D40864B8-CDCB-4EBD-85A0-B4B2CEBD76ACQ21173381-4FE2120B-FCAF-49BE-A43F-FC73E248EBADQ21173406-88C4673B-E9A4-42D7-87F2-566275958495Q21173427-2D032607-EC3F-4D7D-A9A6-29EDFE01AFB6Q5629167-5B8C1A3B-6FBF-4378-B591-A3E43C46ED45Q5773155-1B245739-1D7E-45FD-8880-F656FCBE170EQ5773160-F9F56CF7-BF06-481F-8CAC-B4B9197AB919
P129
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Vorinostat
@de
Vorinostat
@en-ca
Vorinostat
@en-gb
Vorinostat
@es
Vorinostat
@nl
Vorinostat
@pt-br
Vorinostat
@ro
Vorinostat
@sh
Vorinostat
@sr
Vorinostat
@vi
type
label
Vorinostat
@de
Vorinostat
@en-ca
Vorinostat
@en-gb
Vorinostat
@es
Vorinostat
@nl
Vorinostat
@pt-br
Vorinostat
@ro
Vorinostat
@sh
Vorinostat
@sr
Vorinostat
@vi
altLabel
Octanedioic acid hydroxyamide phenylamide
@en
SAHA
@en
SAHA
@pl
SHH
@en
Suberoylanilide hydroxamic acid
@en
Zolinza
@de
kwas suberanilohydroksamowy
@pl
octanedioic acid hydroxyamide phenylamide
@en
suberanilohydroxamic acid
@en
suberoylanilide hydroxamic acid
@en
prefLabel
Vorinostat
@de
Vorinostat
@en-ca
Vorinostat
@en-gb
Vorinostat
@es
Vorinostat
@nl
Vorinostat
@pt-br
Vorinostat
@ro
Vorinostat
@sh
Vorinostat
@sr
Vorinostat
@vi